Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxelotor effects on cerebral perfusion and oxygenation in adults with sickle cell disease
NL-OMON52775Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Amsterdam University Medical Center. Primary endpoint: Cerebral vascular reserve capacity. Started Feb 2021; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON52775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52775.